Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial

About this item

Title

Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial

Content partner

FigShare

Collection

FigShare

Description

BackgroundThe Vaxxas high-density microarray patch (HD-MAP) consists of a high density of microprojections coated with vaccine for delivery into the skin. Microarray patches (MAPs) offer the possibility of improved vaccine thermostability as well as the potential to be safer, more acceptable, easier to use, and more cost-effective for the administration of vaccines than injection by needle and syringe (N&S). Here, we report a phase I trial using the Vaxxas HD-MAP to deliver a monovalent influ...

Read more

Format

Data

Date created

17 Mar, 2020

Creator

Angus H. Forster / Katey Witham / Alexandra C. I. Depelsenaire / Margaret Veitch / James W. Wells / Adam Wheatley / Melinda Pryor / Jason D. Lickliter / Barbara Francis / Steve Rockman / Jesse Bodle / Peter Treasure / Julian Hickling / Germain J. P. Fernando

URL

https://figshare.com/articles/dataset/Safety_tolerability_and_immunogenicity_of_influenza_vaccina...

Related subjects

MBC / T-cell cytokine production / quadrivalent influenza vaccine / memory B cell / HAI / IM-QIV -15 / influenza vaccine / Vaxxas HD-MAP delivery / 9 treatment groups / monovalent influenza vaccine / ID / MAP-UA / MN / UA / IM-A / 60 days post-vaccination / 1N / microarray patch / 2.5 μ g HA / Conclusions Influenza vaccine / CI / HD-MAP application sites / GMT / IM injection / ACTRN / MAP-FA -10 / AE / influenza virus vaccine / 15 μ g HA / New Zealand Clinical Trials Registry / IM-QIV -15 group / Space Science / Medicine / Microbiology / Cell Biology / Neuroscience / Biotechnology / Environmental Sciences not elsewhere classified / Science Policy / Immunology / Infectious Diseases / Virology

What is the copyright status of this item?

Creative Commons

This item appears to be licensed under a Creative Commons (ZERO) 1.0 CC International license.

More Information

FigShare has this to say about the rights status of this item:

http://figshare.com/licensing

You can learn more about the rights status of this item at: http://creativecommons.org/publicdomain/zero/1.0/

What can I do with this item?

You must always check with FigShare to confirm the specific terms of use, but this is our understanding:

Non-infringing use

NZ Copyright law does not prevent every use of a copyright work. You should consider what you can and cannot do with a copyright work.

Share it

This item is suitable for copying and sharing with others, without further permission.

Modify it

This item is suitable for modifying, remixing and building upon, without further permission.

Use it commercially

This item is suitable for commercial use, without further permission.